From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Routes of
ATC code
  • None
Legal status
Legal status
  • Development terminated
CAS Number
PubChem CID
Chemical and physical data
Molar mass617.76 g·mol−1

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalable[1] ultra-long-acting β2 adrenoreceptor agonist[2] (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer.[3] It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events.[4] Its in vivo duration on action confirmed its potential for once-daily use in humans. [5]

The investigation and development of PF-610355 were discontinued in 2011,[6] likely for strategic and regulatory reasons.[7]


  1. ^ Diderichsen, Paul Matthias; Cox, Eugène; Martin, Steven W.; Cleton, Adriaan; Ribbing, Jakob (November 2013). "Predicted Heart Rate Effect of Inhaled PF-00610355, a Long Acting β-Adrenoceptor Agonist, in Volunteers and Patients With Chronic Obstructive Pulmonary Disease". British Journal of Clinical Pharmacology. 76 (5): 752–62. doi:10.1111/bcp.12080. PMC 3853534. PMID 23323609.
  2. ^ Cazzola, Mario; Luigino Calzetta; Maria Gabriella Matera3 (May 2011). "β2-adrenoceptor agonists: current and future direction". Br J Pharmacol. 163 (1): 4–17. doi:10.1111/j.1476-5381.2011.01216.x. PMC 3085864. PMID 21232045.
  3. ^ "Pfizer Pipeline as of January 27, 2010" (PDF). Pfizer Inc. p. 6. Retrieved 9 April 2016.
  4. ^ Glossop, PA; Lane, CA; Price, DA; Bunnage, ME; Lewthwaite, RA; James, K; Brown, AD; Yeadon, M; Perros-Huguet, C; Trevethick, MA; Clarke, NP; Webster, R; Jones, RM; Burrows, JL; Feeder, N; Taylor, SC; Spence, FJ (23 September 2010). "Inhalation by Design: Novel Ultra-Long-Acting β2-Adrenoreceptor Agonists for Inhaled Once-Daily Treatment of Asthma and Chronic Obstructive Pulmonary Disease That Utilize a Sulfonamide Agonist Headgroup". Journal of Medicinal Chemistry. 53 (18): 6640–52. doi:10.1021/jm1005989. PMID 20804199.
  5. ^ Acton, Q. Ashton (ed.). Issues in Medical Chemistry. 2011 Edition. ScholarlyEditions. ISBN 978-1-464-96440-4.
  6. ^ "AdisInsight: PF 610355". Springer International Publishing AG. Retrieved 25 March 2016.
  7. ^ Cazzola, M; Page, CP; Rogliani, P; Matera, MG (1 April 2013). "β2-Agonist Therapy in Lung Disease". American Journal of Respiratory and Critical Care Medicine. 187 (7): 693. doi:10.1164/rccm.201209-1739PP. PMID 23348973.